Postpartum depression

Patient speaking to psychiatrist

First oral drug for postpartum depression approved in US

7 August 2023

The US Food and Drug Administration (FDA) has approved Sage Therapeutics’ Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. Until now, treatment for PPD was only available as an IV injection given by a health care provider in certain health care facilities. “Postpartum depression is a serious and potentially […]

Potential treatment for anxiety and postpartum depression 

3 March 2023

PureTech Health, a clinical-stage biotherapeutics company, will advance therapeutic candidate LYT-300 (oral allopregnanolone) for the potential treatment of anxiety disorders and postpartum depression (PPD).    A social anxiety clinical trial in healthy volunteers is expected to begin in the first half of 2023, with results anticipated by the end of 2023; a clinical trial in women […]